2
Clinical Trials associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute) / Unknown statusNot ApplicableIIT Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
This is a Phase I/II clinical trial of gene transfer for treating Beta-thalassemia using a self-inactivating lentiviral vector to functionally correct the defective gene(s). The objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
/ Unknown statusNot ApplicableIIT Gene Transfer for Fanconi Anemia Using a Self-inactivating Lentiviral Vector
This is a Phase I/II clinical trial of gene therapy for treating Fanconi anemia using a self-inactivating lentiviral vector to functionally correct the defective gene. The objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
100 Clinical Results associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
100 Translational Medicine associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
100 Patents (Medical) associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)
100 Deals associated with Gene-modified autologous stem cell therapy (Shenzhen Geno-Immune Medical Institute)